INDIANAPOLIS, Oct. 28, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of $1.30 per share on outstanding ...

Of Lilly’s $3.11 billion in quarterly sales from Mounjaro, $2.4 billion came from the U.S. Related Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...

Eli Lilly has brought in billion-dollar revenue from its weight loss drugs -- but short supply has limited the revenue opportunity. The FDA earlier this month recognized Lilly’s progress in ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Five months after Eli Lilly secured the first of two approvals for tirzepatide in China—one for Type 2 diabetes and the other for obesity—the company has revealed that it will expand its ...

Lilly Ledbetter, whose gender pay equity legal fight was the inspiration for the Fair Pay Act of 2009, has died at age 86. Ledbetter died of respiratory failure, her family said in a statement ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the ...

Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on technology to deliver siRNA molecules it discovered using its machine learning ...

Eli Lilly (NYSE: LLY) stock has climbed in the double digits over the past year thanks to its leading position in one of the highest-growth pharmaceutical markets around: weight loss drugs.

Eli Lilly’s Third Quarter Earnings Miss and Forecast Cut Lead to Sharp Stock Drop INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third ...